Antifibrotic effects of aldosterone receptor blocker (Spironolactone) in patients with chronic kidney disease

Renal Failure

Volumn 31, Issue 9, 2009, Pages 779-784

  Guney, Ibrahim ^a   Selcuk, N Yilmaz ^b   Altintepe, Lutfullah ^c   Atalay, Huseyin ^b   Başarali, M Kemal ^b   Büyükbaş, Sadik ^b  

^a Konya Research and Training Hospital   (Turkey)

^b SELCUK UNIVERSITY   (Turkey)

^c Meram Training and Research Hospital   (Turkey)

Author keywords

Chronic kidney disease; Proteinuria; Spironolactone; TGF 1

Indexed keywords

ALBUMIN; ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG EFFECT; DRUG MECHANISM; ECHOGRAPHY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BIOPSY; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; URINALYSIS;

ADRENERGIC ANTAGONISTS; ADULT; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE PROGRESSION; FEMALE; FIBROSIS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 71049132261     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860220903150312     Document Type: Article

References (28)

1. Collins AJ, Kasiske B, Herzog C, et al. United States Renal Data System. Excerpts from the United States Renal Data System 2004 Annual Data Report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2005;45(1 Suppl. 1):A5-A7.
2. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-b pathway. Kidney Int. 2006;70:1914-1919.
3. Hill GS, Delahousse M, Nochy D, Mandet C, Bariéty J. Proteinuria and tubulointerstitial lesions in lupus nephritis. Kidney Int. 2001;60(5):1893-1903.
4. Reeves WB, Andreoli TE. Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA. 2000;97:7667-7669.
5. Tylicki L, Larczynski W, Rutkowski B. Renal protective effects of the renin-angiotensin-aldosterone system blockade: From evidence-based approach to perspectives. Kidney Blood Press Res. 2005;28:230-242.
6. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl. 2005;99:S57-S65.
7. Sato A, Saruta T. Aldosterone escape during angiotensinconverting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res. 2001;29:13-21.
8. Naruse M, Tanabe A, Sato A, et al. Aldosterone breakthrough during angiotensin II receptor antagonist theraphy in stroke-prone spontaneously hypertensive rats. Hypertension. 2002;40:28-33.
9. Epstein M. Aldosterone blockade: An emerging strategy for abrogating progressive renal disease. Am J Med. 2006;119:912-919.
10. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int. 2004;66:1-9.
11. Honkanen E, Teppo A-M, Törnroth T, Groop PH, Grönhagen-Riska C. Urinary transforming b1 in membranous glomerulonephritis. Nephrol Dial Transplant. 1997;12:2562-2568.
12. De Muro P, Faedda R, Fresu P, et al. Urinary transforming growth factor b1 in various types of nephropathy. Pharmacol Res. 2004;49:293-299.
13. Korpinen E, Teppo A-M, Hukkanen L, Akerblom H, Gronhagen-Riska C, Vaarala O. Urinary transforming growth factor-b1 and a1-macroglobulin in children and adolescents with type-1 diabetes. Diabetes Care. 2000;23:664-668.
14. Song JH, Cha SH, Lee HJ et al. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-b in type 2 diabetic patients with advanced kidney disease. Nephrol Dial Transplant. 2006;21:683-689.
15. Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266.
16. Struthers AD, MacDonald TM. Review of aldosterone-and angiotensin II-induced target organ damage and prevention. Cardiovasc Res. 2004;61(4):663-670.
17. Liang YH, Wang JM, Zhou Y, Jiang XJ, Jiang H, Huang CX. Additive effects of combined valsartan and spironolactone on cardiac aldosterone escape in spontaneously hypertensive rats. Life Sci. 2004;75(15):1871-1878.
18. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med. 2001;345:925-926.
19. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study. Am J Kidney Dis. 2005;46:45-51.
20. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70:2116-2123.
21. Schjoedt KJ, Rossing K, Juhl TR, et al. Benefical impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70:536-542.
22. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. AJH. 2005;18:44-49.
23. Gullulu M, Akdag I, Kahvecioglu S, et al. Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well. Renal Failure. 2006;28:509-514.
24. Feria I, Pichardo I, Juárez P, et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int. 2003;63:43-52.
25. Tsakas S, Goumenos DS. Accurate measurement and clinical significance of urinary transforming growth factor-beta 1. Am J Nephrol. 2006;26:186-193.
26. Song JH, Lee SW, Suh JH et al. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in two groups of patients with IgA and diabetic nephropathy. Clin Nephrol. 2003;60:318-326.
27. Park HC, Xu ZG, Choi S, et al. Effect of losartan and amlodipine on proteinuria and transforming growth factor-b1 in patients with IgA nephropathy. Nephrol Dial Transplant. 2003;18:1115-1121.
28. Furumatsu Y, Nagasawa Y, Tomida K, et al. Effect of renin-angiotensin- aldosterone system triple blockade on non-diabetic renal disease: Addition of an aldosterone blocker, spironolactone, to combination enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res. 2008;31:59-67.